Publications

Chromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC Inhibitors.
Cancer Cell 2017 Jul 15;32(1):27-41.e4. Epub 2017 Jun 15.
Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Stanford University School of Medicine, CCSR 2155c, 269 Campus Drive, Stanford, CA 94305-5168, USA; Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address:

Freeze and Thaw of CD4+CD25+Foxp3+ Regulatory T Cells Results in Loss of CD62L Expression and a Reduced Capacity to Protect against Graft-versus-Host Disease.
PLoS One 2015 22;10(12):e0145763. Epub 2015 Dec 22.
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
J Clin Oncol 2015 Nov 20;33(32):3750-8. Epub 2015 Jul 20.
Youn H. Kim, Mahkam Tavallaee, Uma Sundram, Shufeng Li, Sima Rozati, Seema Nagpal, Michael Krathen, Sunil Reddy, Richard T. Hoppe, Annie Nguyen-Lin, Wen-Kai Weng, Randall Armstrong, and Ranjana H. Advani, Stanford University, Stanford, CA; Katrin A. Salva and Gary S. Wood, University of Wisconsin and William S. Middleton Memorial Veterans Hospital, Madison, WI; and Melissa Pulitzer and Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, NY.



The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Am J Hematol 2012 Apr 24;87(4):354-60. Epub 2012 Feb 24.
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 , USA.

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
Proc Natl Acad Sci U S A 2011 Dec 12;108(52):21194-9. Epub 2011 Dec 12.
Divisions of Blood and Marrow Transplantation and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant 2011 Nov 25;17(11):1679-87. Epub 2011 May 25.
Division of Blood and Marrow Transplantation, Stanford University School of Medicine, 300 Pastaur Drive, Stanford, CA 94305, USA.

OF